KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Other Non-Current Liabilities (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of Other Non-Current Liabilities data on record, last reported at $5.0 million in Q3 2025.

  • For Q3 2025, Other Non-Current Liabilities fell 27.3% year-over-year to $5.0 million; the TTM value through Sep 2025 reached $5.0 million, down 27.3%, while the annual FY2024 figure was $7.2 million, 56.22% up from the prior year.
  • Other Non-Current Liabilities reached $5.0 million in Q3 2025 per NKTR's latest filing, down from $5.6 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $27.7 million in Q4 2021 and bottomed at $4.3 million in Q1 2024.
  • Average Other Non-Current Liabilities over 5 years is $8.6 million, with a median of $6.6 million recorded in 2023.
  • Peak YoY movement for Other Non-Current Liabilities: surged 549.86% in 2021, then plummeted 72.77% in 2022.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $27.7 million in 2021, then tumbled by 72.77% to $7.6 million in 2022, then crashed by 38.62% to $4.6 million in 2023, then skyrocketed by 56.22% to $7.2 million in 2024, then plummeted by 30.6% to $5.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Liabilities were $5.0 million in Q3 2025, $5.6 million in Q2 2025, and $6.8 million in Q1 2025.